Scribe Therapeutics grants 14,725 stock options to director

Scribe Therapeutics, Inc. director James Dean Watson received a grant of stock options for 14,725 shares of Common Stock on July 23, 2026.

Rhea-AI Filing Summary

Scribe Therapeutics, Inc. director James Dean Watson received a grant of stock options for 14,725 shares of Common Stock on July 23, 2026. These options have a conversion/exercise price of $15.00 per share and expire on July 22, 2036. Following this grant, he holds options for 14,725 shares directly.

The options will vest in three equal installments of one-third of the total shares on July 23, 2027, July 23, 2028, and July 23, 2029, subject to his continued service to Scribe Therapeutics on each vesting date.

Insider Trade Summary

Grant/Award: 14,725 shares

Grant/Award 1 txn

Insider Watson James Dean

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	14,725	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 14,725 contracts (Direct)

Footnotes (1)

1. F1. The options will vest as to 1/3 of the total shares on each of July 23, 2027, July 23, 2028 and July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Key Figures

Options granted: 14,725 shares Exercise price: $15.00 per share Expiration date: July 22, 2036 +3 more

6 metrics

Options granted 14,725 shares Stock Option (Right to Buy) award on July 23, 2026

Exercise price $15.00 per share Conversion or exercise price of granted stock options

Expiration date July 22, 2036 Expiration of Stock Option (Right to Buy)

Underlying shares 14,725 shares Underlying Common Stock covered by the option grant

Post-grant option holdings 14,725 shares Total options held directly following the transaction

Vesting dates July 23, 2027; July 23, 2028; July 23, 2029 One-third of options vesting on each listed date

Key Terms

Stock Option (Right to Buy), exercise price, vesting, expiration date

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion/exercise price of $15.00 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The options will vest as to 1/3 of the total shares"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration date: 2036-07-22 for the stock options"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Scribe Therapeutics (SCTX) report for James Dean Watson?

James Dean Watson received a grant of stock options for 14,725 shares of Scribe Therapeutics Common Stock on July 23, 2026, reported as a derivative acquisition under a stock option award.

What is the exercise price of the new SCTX stock options granted to James Dean Watson?

The granted stock options have an exercise price of $15.00 per share. This means Watson may purchase Scribe Therapeutics Common Stock at $15.00 per share upon exercise of these options, subject to vesting and expiration terms.

How many Scribe Therapeutics (SCTX) options does James Dean Watson hold after this Form 4?

After the reported grant, James Dean Watson holds options for 14,725 shares of Scribe Therapeutics Common Stock directly, as shown by the total shares following the transaction field.

When do James Dean Watson’s Scribe Therapeutics (SCTX) options vest?

The options vest in three equal installments: one-third on July 23, 2027, one-third on July 23, 2028, and one-third on July 23, 2029, contingent on continued service on each vesting date.

When do the newly granted Scribe Therapeutics (SCTX) stock options expire?

The stock options granted to James Dean Watson expire on July 22, 2036. After that expiration date, any unexercised portion of the 14,725-share option award will no longer be exercisable.

Is the reported SCTX Form 4 transaction a purchase or a grant of options?

The Form 4 reports a grant/award acquisition of stock options, coded as transaction type “A” for a Stock Option (Right to Buy), rather than an open-market purchase or sale of Scribe Therapeutics shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/10/2026 - 04:00 PM Accepted by SEC EDGAR 07/27/2026 - 09:23 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Watson James Dean

(Last) (First) (Middle)

C/O SCRIBE THERAPEUTICS INC.

1150 MARINA VILLAGE PARKWAY

(Street)

ALAMEDA CALIFORNIA 94501

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Scribe Therapeutics, Inc. [ SCTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$15	07/23/2026		A		14,725		(1)	07/22/2036	Common Stock	14,725	$0	14,725	D

Explanation of Responses:

1. The options will vest as to 1/3 of the total shares on each of July 23, 2027, July 23, 2028 and July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

	/s/ David L. Parrot, Attorney-in-Fact	07/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)